Polidocanol endovenous microfoam 1% (PEM, Boston Scientific Corporation) has gained widespread acceptance for treating venous insufficiency. Clinical trials of PEM report mild to moderate adverse events in 60% of trial participants, one of the most common being retained intravascular coagulum (IC). This study aims to identify risk factors that lead to increased incidence of IC observed in clinical practice.
No takes yet. Share an insight, caveat, or question.
Mesa et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: